pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$TNGXTango Therapeutics, Inc.

$TNGX23.89+9.77%
Boston, MA, USupdated 13d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 2: 3
3Phase 2
Phase 2
TNG-260
Cervical Cancer
Phase 2
TNG-456
Bladder Cancer
Phase 2
vopimetostat
Bladder Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Lossrecruitingn=191
  • phase2Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patientsrecruitingn=183
  • phase2Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumorsrecruitingn=225
  • phase2Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumorsterminatedn=110
  • phase2Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumorsrecruitingn=126
  • phase2Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumorsterminatedn=7
🐶 Hiring Signal
17 open roles at Tango Therapeutics, Inc. →

Where Tango Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 17
departmentCommercial 4Biostatistics / Data 3Quality 2Medical Affairs 2Market Access 1Clinical 1

News

  • Verastem cancer drug shows early promise in small study
    Wall Street analysts believe Verastem’s drug to now be “competitive” in what’s quickly become one of the most active and crowded areas of oncology research.
    biopharma_dive · 1mo ago
  • Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
    Plus news about Parabilis Medicines, RA Capital, Tango Therapeutics, Ideaya Biosciences, Bavarian Nordic and Cartesian Therapeutics 💸 Lilly’s $1B Alzheimer’s deal: The Indianapolis drugmaker will…
    endpoints · 5mo ago
identifiers
ticker
$TNGX
SEC CIK
0001819133
country
US
source
sec_tickers
top tags
NSCLC3Oncology3
mentioned in
2news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 56m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?